Galmed Pharma (GLMD) Tops Q2 EPS by 4c

Galmed Pharma (NASDAQ: GLMD) reported Q2 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Barclays says AI trade is maturing, favors greater diversification
• Ready Capital prices $225M in new notes, redeems $350M due 2026